Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have risen 33.9% in the past six months compared with the industry’s 9.8% growth. The S&P 500 Index has also increased 17.4% in the same time frame.Glaukos, with a market capitalization of $8.66 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-quarter average earnings surprise of 3.24%.Image Source: Zacks Investment ResearchKey CatalystsStrong Product Demand: Glaukos' rising share price is largely driven by the success of its flagship product, iStent. The company delivered robust performance during the first nine months of 2024 and maintains a favorable business outlook, strengthening investors’ confidence. Additionally, the high demand for Glaukos' international glaucoma and Corneal Health products continues to fuel investors’ optimism.On its third-quarter earnings call, Glaukos highlighted the increasing adoption of iStent Infinite for glaucoma patients, particularly those unresponsive to other treatments. This growth has been fueled by enhanced clinical education and improved market access. Furthermore, five out of seven Medicare Administrative Contractors have released draft local coverage determinations for iStent Infinite. This is anticipated to expand patient access.Glaukos’ revenues have surpassed estimates in the first nine months of 2024 due to high demand for its products. Consequently, the company raised its full-year 2024 revenue guidance to $377-$379 million from $370-$376 million, contributing to the rising momentum in its share price. The company’s 2025 sales and earnings are likely to improve 26.2% and 42.8%, respectively.Expanding Product Portfolio: The iStent portfolio significantly boosted Glaukos' glaucoma franchise revenues in the first nine months of 2024. Additionally, the launch of iDose TR in the second quarter of 2024 is already enhancing revenue growth, beginning third quarter. With a permanent J-code for iDose TR effective from July 1, patient access is likely to increase, driving fourth-quarter sales.Recent findings from a 36-month follow-up analysis of two Phase 3 pivotal trials underscore iDose TR’s potential to redefine glaucoma treatment paradigms. At 36 months post-implantation, approximately 70% of patients treated with the iDose TR remained well-controlled on the same or fewer IOP-lowering medications compared to 58% of those in the timolol control group. Results from a phase 4 study highlight the synergy between glaucoma management and cataract surgery, broadening the implant’s potential applications in ophthalmic care.Glaukos continues to invest in its product pipeline, including its corneal cross-linking therapy, Epioxa. The company submitted a new drug application seeking approval for the therapy last month. GKOS has successfully completed two pivotal trials on Epioxa, demonstrating its favorable efficacy, tolerability and safety profiles. It is also preparing for a pivotal study on its next-generation iDose therapy, iDose TREX, which is set to begin soon. These initiatives are poised to drive long-term growth.Internationally, Glaukos is focused on expanding its footprint. The company sells its products through subsidiaries in 17 countries and independent distributors in other markets. Glaukos' international glaucoma franchise reported record sales of $83.5 million in the first nine months of 2024, reflecting 17% year-over-year growth. This global expansion is expected to continue to support the company's long-term growth trajectory.What’s Hurting GKOS?The company currently depends on a limited number of third-party suppliers, including some sole suppliers, for components of the iStent, iStent inject models and other pipeline products. If any of these suppliers fail to provide sufficient quantities of components or drugs in a timely manner or on acceptable terms, Glaukos would need to seek alternative sources.Glaukos Corporation Price Glaukos Corporation price | Glaukos Corporation QuoteEstimate TrendThe bottom-line estimate for GKOS is pegged at a loss of $1.08 per share for 2025, which remained unchanged in the past 30 days. The Zacks Consensus Estimate for 2025 revenues is pinned at $478.1 million.Stocks to ConsiderSome better-ranked stocks in the broader medical space are Cardinal Health, Inc. CAH, ResMed Inc. RMD and Alphatec ATEC.Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.64%. Its shares have risen 27.2% compared with the industry’s 5.6% growth in the past six months.ResMed, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 16%. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.86%.ResMed’s shares have gained 11.5% compared with the industry’s 15.4% growth in the past six months.Alphatec, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 40% for 2025. ATEC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.6%.Alphatec’s shares have rallied 46.4% compared with the industry’s 8.8% growth in the past six months.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Alphatec Holdings, Inc. (ATEC): Free Stock Analysis Report Glaukos Corporation (GKOS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks